XML 18 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]      
Revenues $ 2,743.3 $ 2,539.3 $ 2,225.1
Operating expenses:      
Salaries and benefits 793.8 746.4 644.3
Supplies 745.0 709.7 636.4
Professional and medical fees 296.8 269.2 230.0
Lease expense 84.9 82.4 90.6
Other operating expenses 175.3 156.7 132.4
Cost of revenues 2,095.8 1,964.4 1,733.7
General and administrative expenses 120.9 102.2 104.0
Depreciation and amortization 118.1 114.8 98.8
Transaction and integration costs 61.7 47.5 39.8
Grant funds (1.1) (2.4) (37.9)
Net loss on disposals, consolidations and deconsolidations 14.4 11.1 2.2
Equity in earnings of unconsolidated affiliates (14.2) (12.5) (11.3)
Litigation settlements 10.6 (29.3) 0.0
Loss on debt extinguishment 15.5 14.9 9.1
Other income, net (6.4) (16.6) (15.5)
Total operating expenses 2,415.3 2,194.1 1,922.9
Operating income 328.0 345.2 302.2
Interest expense, net (193.0) (234.9) (221.0)
Income before income taxes 135.0 110.3 81.2
Income tax benefit (expense) 0.3 (23.3) (10.5)
Net income 135.3 87.0 70.7
Less: Net income attributable to non-controlling interests (147.2) (141.6) (141.6)
Net loss attributable to Surgery Partners, Inc. (11.9) (54.6) (70.9)
Less: Amounts attributable to participating securities 0.0 0.0 (10.3)
Net loss attributable to common stockholders (11.9) (54.6) (81.2)
Net loss attributable to common stockholders (diluted) $ (11.9) $ (54.6) $ (81.2)
Net loss per share attributable to common stockholders:      
Basic (in USD per share) $ (0.09) $ (0.59) $ (1.12)
Diluted (in USD per share) [1] $ (0.09) $ (0.59) $ (1.12)
Weighted average common shares outstanding:      
Basic (shares) 125,613 91,952 72,427
Diluted (shares) [1] 125,613 91,952 72,427
[1] The impact of potentially dilutive securities for all periods were not considered because the effect would be anti-dilutive.